Mylan takes majority stake in Matrix

In a move to expand its reach around the globe, Mylan Laboratories has acquired a majority interest in India's Matrix Laboratories for about $735 million. For Mylan, the acquisition gives the company access to emerging markets in India, China and Africa as well as a distribution network in Europe. Analysts immediately indicated that this latest deal would only spur new consolidation in the business as foreign outfits looked to India to help cut their costs during a time of intense price competition in the U.S.

- read the report on the acquisition from CNN-IBN

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.